The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy

Conclusion
The CHA2DS2-VASc score reclassifies 26% of patients with a CHADS2 score of 1 to a low annual risk of SSE of 1%. This risk seems low enough to consider withholding anticoagulant treatment.

Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Coppens, M., Eikelboom, J. W., Hart, R. G., Yusuf, S., Lip, G. Y. H., Dorian, P., Shestakovska, O., Connolly, S. J. Tags: Arrhythmia/electrophysiology Source Type: research